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Abstract 
Viral hepatitis B is a vaccine-preventable disease. Vaccination has
proved to be safe and highly effective in reducing the incidence, the
carrier rate and HBV-related mortality on a global scale. In Italy, uni-
versal vaccination against hepatitis B started in 1991 in infants as well
as in adolescents, providing an outstanding record of safety and effec-
tiveness. Within a few years, over 95% coverage was consistently
reported. Today, some 17 million people are immune against hepatitis
B and their immunity has been shown to be long-lasting. At present,
no booster is required in healthy vaccinated people to sustain protec-
tion. Surveillance data from Italy have shown a clear overall decline in
hepatitis B among successfully vaccinated individuals. Furthermore, a
generation of children and young people (at present cohorts ranging
from 0 to 32 years) is emerging with practically no markers of HBV
infection. Italy’s vaccination programme has resulted in substantial
progress towards the prevention and control of hepatitis B. The vacci-
nation programme must continue. Maintaining mandatory vaccination
of infants and increasing HBV vaccination coverage in high-risk
groups, including households of HBsAg carriers as well as immigrants,
remain a priority for the future.  
Introduction
Viral hepatitis type B is still a major public health problem on a glob-
al scale. Infection with hepatitis B virus (HBV) can progress to chron-
ic liver disease, including cirrhosis and hepatocellular carcinoma
(HCC), which ranks as the third cause of cancer deaths worldwide. 
Vaccination is the most effective measure to control and prevent
hepatitis B in terms of both cost- effectiveness and benefit-cost ratios.
Safe and effective vaccines have been available since the early 1980s
when the so-called plasma-derived vaccines were first introduced and
then largely replaced by yeast-derived recombinant DNA vaccines in
the mid-1980s.
Strategies of vaccination were initially targeted toward groups at
increased behavioural (e.g. injecting drug users, sexually active homo-
sexual men, people with multiple sexual partners), professional (e.g.
health-care workers) risk of infection, to patients like haemophiliacs
and those on dialysis maintenance, and to babies born to hepatitis B
surface antigen (HBsAg) positive mothers.1 Failure of such policies of
vaccination to reduce the impact of hepatitis B in the population at
large led to the WHO recommendation that all countries introduce a
policy of universal infant or adolescent (or both if economically feasi-
ble) hepatitis B vaccination integrated into their national immunisa-
tion programme. At present, 179 countries worldwide have so far
implemented this recommendation or are planning to do.2,3 In the
WHO European region, UK and Scandinavian countries still do not
advocate universal vaccination and have opted (on economic grounds)
for targeted vaccination focussed on well-defined risk groups.      
Globally, several hundred million vaccinations have been adminis-
tered worldwide so far, with an outstanding record of safety and effica-
cy. Vaccination against hepatitis B is well tolerated. Local side effects are
generally mild and confined to symptoms at the site of injection, while
systemic reactions are uncommon. A number of case reports from
France in 1998 and thereafter raised concern that hepatitis B vaccina-
tion may lead to new cases or relapses of multiple sclerosis or other neu-
rological disorders, but no clear causal link was established.4-9
There is evidence to indicate that anti-HBs (hepatitis B surface
antibodies) seroprotection (concentration ≥10 mU/mL) rates are close
to 100% in healthy children and over 95% in healthy adults, and that
protective antibodies are long-lasting since they may persist for at
least 15-20 years.10-15 Vaccinees who have lost antibody usually show a
rapid anamnestic response when boosted.13,14,16-18 This means that the
immunological memory outlasts antibody detection providing protec-
tion against clinical disease and the development of carrier state.19-21
Thus, current evidence shows that there is no need for a booster in the
general population. However, some long-term protection studies have
recently shown an increasing number of people with no evidence of
boostability (failure to respond to a booster); the reason for this find-
ing and its significance should be further investigated.13,16,22,23
Vaccination has been proved to reduce the incidence, carrier rates,
and mortality related to hepatitis B.24 In Taiwan, where mass vaccina-
tion of newborns was first introduced in 1984, the HBsAg carrier rates
among children dropped from 9.8% in the year prior immunisation to
0.6% in 2004.25 Furthermore, the annual average incidence of HCC
declined significantly after the implementation of vaccination, demon-
strating that hepatitis B vaccine can prevent a major human can-
cer.26,27 Likewise, in other hyperendemic countries such as the
Gambia, Malaysia and Alaska, vaccination has clearly proven to be very
Significance for public health
This study is a historical overview on the global impact of vaccination against
hepatitis B. Viral hepatitis B is a leading cause of acute and chronic liver dis-
ease, including cirrhosis and liver cancer. Hepatitis B is the most effective
measure to control and prevent hepatitis B and its long-term sequelae.
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tributed to the saving of lives, prevention of suffering, and savings to the
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successful.28-30 On the whole, following vaccination, remarkable
progress has been achieved in terms of global control and prevention of
hepatitis B. However, much remains to be done to meet the WHO goal
by overriding the economic barriers that still hamper the introduction
of this vaccination in some countries with low resources and high
endemicity.
The Italian vaccination programme and itsimpact
A vaccine against hepatitis B was first introduced in Italy in 1981 for
the immunisation of haemodialysis patients and their staff.31 In 1983,
a selective programme started using the vaccine in targeted campaigns
among at-risk populations. The results encouraged a broader introduc-
tion of the vaccine and in 1988 a decree identified subjects at increased
risk for hepatitis B to whom vaccination would be offered free of
charge. Then, in 1991, a law was passed mandating the universal vac-
cination of infants and 12-year old adolescents (restricted to the first
12 years of the implementation of the vaccination law) on a national
scale.32-35 This programme also includes mandatory screening for
HBsAg of pregnant women in order to identify babies in need of treat-
ment with hepatitis B immune globulins (HBIG) and vaccine at birth,
and recommendation for vaccination of high-risk groups free of charge.
By the end of 2003, the first infant cohort vaccinated in 1991 reached
the age (12 years) at which adolescent vaccination was programmed.
Thus, in 2004, vaccination of 12-year old adolescents was stopped and
that of infants maintained. 
Before the mandatory vaccination, a wealth of published epidemio-
logical and clinical data on the national burden of the disease and those
collected by the National Surveillance System for Acute Viral Hepatitis
(SEIEVA) prepared the ground by studiously tracking the presence of
hepatitis B in the country, emphasizing the need to urgently implement
control and preventive measures.
Take-up of the vaccine was rapid and within a few years over 95%
coverage was consistently reported. Today, some 17 million young peo-
ple are immune against hepatitis B and their immunity has been
shown to be long-lasting.13 Data collected prior- and post-vaccination by
SEIEVA, clearly show that rates of hepatitis B virus infection fell dra-
matically. Although the decline in incidence of hepatitis B had started
before the mandatory introduction of the vaccine as a result of improv-
ing socioeconomic conditions, demographic changes (smaller fami-
lies), better hygiene and the changes in risky behaviour resulting from
anti-AIDS campaigns, refinement in blood screening, and adoption of
universal precautions in medical settings, the vaccine ensured that the
efforts made towards elimination of the disease were worthwhile.
Since the mandatory introduction of universal hepatitis B vaccination,
the incidence of the disease has fallen from 5.1 per 100,000 inhabitants
in 1991 to 0.9 cases per 100,000 in 2010. The decline was even more
remarkable in 15-24-year-old individuals where incidence per 100,000
dropped from 17 to less than 0.5 in the same period of time.36
Furthermore, prevalence of markers of HBV infection (HBsAg and/or
anti-HBc) declined dramatically after the introduction of the vaccina-
tion programme.37 In addition to the decline of hepatitis B, cases of
hepatitis delta, which depends on the presence of the hepatitis B virus,
are now rarely reported.38
Cases of hepatitis B in vaccinated individuals have rarely been report-
ed to SEIEVA and they were generally confined to those who did not com-
plete the vaccination schedule properly. Infections caused by HBV-
mutants, including the prototype glycine to arginine substitution G145R
(first identified in Italy some 25 years ago in babies born to HBsAg car-
rier mothers and treated at birth with HBIG and vaccine), are very occa-
sionally the causes of breakthrough infections in successfully vaccinated
people.39-42 Despite the initial concern that these S-gene mutants could
evade vaccine-induced immunity and infect vaccinated people, for the
moment, they are not known to pose a public health threat.
The issue of hexavalent vaccines 
In 2000, two hexavalent vaccines (Hexavac, Sanofi Pasteur MSD and
Infanrix, Glaxo Smith Kline) were licensed in Europe for vaccinating
children against diphtheria, pertussis, poliomyelitis, hepatitis B, and
invasive infections caused by Haemophilus influenzae b. In 2005,
Hexavac was suspended by the European Medicines Agency (EMA) due
to concerns about long-term protection against hepatitis B.43 No action
was taken over Infanrix since immunogenicity of its hepatitis B com-
ponent did not raise equal concern. Until suspension, approximately 10
million doses of Hexavac had been distributed globally, of which almost
90% were used for immunisation of infants in Germany, Austria, and
Italy. So the crucial question was whether infants vaccinated with
Hexavac were protected or required a booster vaccination to sustain
immunity. A large randomised, multicentre study carried out in Italy
showed that five years after primary immunisation, Hexavac albeit less
immunogenic than Infanrix, induced immune memory.44 Therefore, it
can be inferred that if such vaccinated children are exposed to HBV, the
immune memory rapidly induces a vigorous anamnestic response that
prevents acute disease and the development of a chronic carrier state.
In other words, even children who have lost protective antibody concen-
trations may still maintain T-cell memory that is able to trigger anti-
HBs production by B cells following activation by revaccination or by
natural exposure to HBV.45,46 Thus, the main message from this finding
is that routine booster doses of vaccine do not seem necessary to sus-
tain immunity in children primed with hexavalent vaccines. However,
additional follow up is needed to see whether immunological memory
persists during adolescence and adulthood, when risk of HBV exposure
does significantly increase, or whether a booster may be needed later
in life to maintain lifelong protection.   
Conclusions and what the future holds   
Vaccination has proved successful in Italy. Our findings compare well
with data reported in previously highly endemic countries (e.g. Taiwan,
the Gambia, Alaska) where the impact of vaccination in terms of reduc-
tion in incidence, in carrier rate, and in HBV-related mortality has been
highly impressive. 
Economic analyses show enormous benefits to the country at large
as well as to individuals, and projections up to 2060 indicate that elim-
ination of hepatitis B will have paid for itself and covered the costs of
the campaigns many times over. 
The Italian vaccination programme must continue until every gener-
ation has been immunized. Increasing the HBV vaccination coverage
in high-risk-groups, including households of HBsAg carriers and immi-
grants coming from highly endemic countries, must be a priority. New
antiviral treatments are being introduced, offering hope to the 600,000
or so people (mainly over the fifth decade of life) who remain carriers
of HBV in the country (compared with 2 million 20 years ago) and those
who still contract the disease. The success of Italy’s hepatitis B vacci-
nation programme should pave the way for the introduction of new vac-
cines both nationally and in other countries, as well as reinvigorating
existing campaigns against vaccine-preventable diseases.
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